ATE181835T1 - Wundbehandlung mittels biologisch aktiver peptide - Google Patents

Wundbehandlung mittels biologisch aktiver peptide

Info

Publication number
ATE181835T1
ATE181835T1 AT91902831T AT91902831T ATE181835T1 AT E181835 T1 ATE181835 T1 AT E181835T1 AT 91902831 T AT91902831 T AT 91902831T AT 91902831 T AT91902831 T AT 91902831T AT E181835 T1 ATE181835 T1 AT E181835T1
Authority
AT
Austria
Prior art keywords
biologically active
wound treatment
active peptides
wound
host
Prior art date
Application number
AT91902831T
Other languages
English (en)
Inventor
Barry Berkowitz
Leonard S Jacob
Michael Zasloff
Original Assignee
Magainin Sciences Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Magainin Sciences Inc filed Critical Magainin Sciences Inc
Application granted granted Critical
Publication of ATE181835T1 publication Critical patent/ATE181835T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/08—Linear peptides containing only normal peptide links having 12 to 20 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A61K38/1751—Bactericidal/permeability-increasing protein [BPI]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/001—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof by chemical synthesis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4742—Bactericidal/Permeability-increasing protein [BPI]

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Zoology (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Marine Sciences & Fisheries (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Toxicology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Saccharide Compounds (AREA)
AT91902831T 1989-12-18 1990-12-12 Wundbehandlung mittels biologisch aktiver peptide ATE181835T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US07/451,777 US5045531A (en) 1989-12-18 1989-12-18 Wound treatment employing biologically active ion channel forming peptides and proteins

Publications (1)

Publication Number Publication Date
ATE181835T1 true ATE181835T1 (de) 1999-07-15

Family

ID=23793638

Family Applications (1)

Application Number Title Priority Date Filing Date
AT91902831T ATE181835T1 (de) 1989-12-18 1990-12-12 Wundbehandlung mittels biologisch aktiver peptide

Country Status (10)

Country Link
US (2) US5045531A (de)
EP (1) EP0505497B1 (de)
JP (1) JPH05504566A (de)
AT (1) ATE181835T1 (de)
CA (1) CA2032059C (de)
DE (1) DE69033200T2 (de)
DK (1) DK0505497T3 (de)
ES (1) ES2136599T3 (de)
GR (1) GR3031459T3 (de)
WO (1) WO1991008758A1 (de)

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA1327311C (en) * 1987-07-06 1994-03-01 Jesse M. Jaynes Therapeutic antimicrobial polypeptides, their use and methods for preparation
US5861478A (en) * 1987-07-06 1999-01-19 Helix Biomedix, Inc. Lytic peptides
WO1989000194A1 (en) 1987-07-06 1989-01-12 Louisiana State University Agricultural And Mechan Inhibition of eucaryotic pathogens and neoplasms and stimulation of fibroblasts and lymphocytes with lytic peptides
US5912231A (en) * 1989-07-07 1999-06-15 Scripps Clinic And Research Foundation Substitution analogues of magainin peptides
US5242902A (en) * 1989-09-06 1993-09-07 The Regents Of The University Of California Defensin peptide compositions and methods for their use
NZ237202A (en) * 1990-02-23 1994-01-26 Bristol Myers Squibb Co Composition containing beta-lactam antibiotic and cationic oligopeptide
AU648140B2 (en) * 1991-02-01 1994-04-14 Virtual Drug Development, Inc. Reverse antimicrobial peptides and antimicrobial compositions
WO1993001723A1 (en) * 1991-07-25 1993-02-04 Magainin Pharmaceuticals, Inc. Prophylaxis and treatment of adverse oral conditions with biologically active peptides
US5656456A (en) * 1992-07-13 1997-08-12 Bionebraska, Inc. Chemical method for selective modification of the N- and/or C-terminal amino acid α-carbon reactive group of a recombinant polypeptide or a portion thereof
ATE225801T1 (de) * 1992-07-13 2002-10-15 Bionebraska Inc Verfahren zur modifizierung rekombinanter polypeptide
US5593866A (en) * 1992-08-21 1997-01-14 The University Of British Columbia Cationic peptides and method for production
AU6251594A (en) * 1993-02-26 1994-09-14 Magainin Pharmaceuticals, Inc. Treatment of cancerous growths with biologically active peptides and protease inhibitors
US5733872A (en) * 1993-03-12 1998-03-31 Xoma Corporation Biologically active peptides from functional domains of bactericidal/permeability-increasing protein and uses thereof
US5561107A (en) * 1993-06-04 1996-10-01 Demeter Biotechnologies, Ltd. Method of enhancing wound healing by stimulating fibroblast and keratinocyte growth in vivo, utilizing amphipathic peptides
US5968904A (en) * 1993-06-04 1999-10-19 Demegen, Inc. Modified arginine containing lytic peptides and method of making the same by glyoxylation
US5856178A (en) * 1993-08-30 1999-01-05 Utah State University DNA cassettes for expression of lytic peptides in mammalian cells and transgenic organisms containing same
KR960704524A (ko) * 1993-10-25 1996-10-09 카롤 질레스피 디피신을 함유한 리포좀(liposomal defensins)
AU1086595A (en) 1993-11-08 1995-05-29 Demeter Biotechnologies, Ltd. Methylated lysine-rich lytic peptides and method of making same by reductive alkylation
US6057291A (en) 1995-06-02 2000-05-02 University Of British Columbia Antimicrobial cationic peptides
FR2735983B1 (fr) 1995-06-29 1997-12-05 Centre Nat Rech Scient Peptide permettant de modifier l'activite du systeme immunitaire humain ou animal
US6191254B1 (en) 1995-08-23 2001-02-20 University Of British Columbia Antimicrobial cationic peptides
US6077826A (en) * 1996-01-25 2000-06-20 Kansas State University Research Foundation Synthetic macromolecular channel assembly for transport of chloride ions through epithelium useful in treating cystic fibrosis
JP4048565B2 (ja) * 1996-04-23 2008-02-20 東レ株式会社 「抗ピロリ菌剤」
DE10051983A1 (de) * 2000-10-20 2002-06-13 Beate Kehrel Inhibierung der pathogenen Wirkung oxidierter Proteine
WO2005094423A2 (en) * 2004-02-26 2005-10-13 President And Fellows Of Harvard College Selective inhibition of proteasomes of tuberculosis and other bacteria
WO2009070564A2 (en) * 2007-11-27 2009-06-04 Macrochem Corporation Compositions and methods for prevention of infection in transcutaneous osseointegrated implants
US11174288B2 (en) 2016-12-06 2021-11-16 Northeastern University Heparin-binding cationic peptide self-assembling peptide amphiphiles useful against drug-resistant bacteria

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4507230A (en) * 1982-05-12 1985-03-26 Research Corporation Peptide synthesis reagents and method of use
US4863899A (en) * 1983-05-09 1989-09-05 Todaro George J Biologically active polypeptides
US4734399A (en) * 1985-08-06 1988-03-29 Hoffmann-La Roche Inc. Growth hormone releasing factor analogs
US4810777A (en) * 1987-03-04 1989-03-07 The United States Of America As Represented By The Department Of Health And Human Services Antimicrobial compounds
DE3852636T2 (de) * 1987-12-24 1995-05-04 Gropep Pty Ltd Peptid-analoge vom insulinähnlichen wachstums-faktor 1 (igf-1) oder faktor 2 (igf-2).
US4962277A (en) * 1988-12-09 1990-10-09 Scripps Clinic And Research Foundation Deletion analogues of magainin peptides
US5073542A (en) * 1989-06-07 1991-12-17 Magainin Sciences Inc. CPF peptide compositions and their use in inhibiting growth of target cells or a virus

Also Published As

Publication number Publication date
EP0505497A1 (de) 1992-09-30
DE69033200D1 (de) 1999-08-12
CA2032059A1 (en) 1991-06-19
EP0505497B1 (de) 1999-07-07
WO1991008758A1 (en) 1991-06-27
CA2032059C (en) 2003-02-25
EP0505497A4 (en) 1993-09-08
ES2136599T3 (es) 1999-12-01
DK0505497T3 (da) 1999-11-22
US5045531A (en) 1991-09-03
DE69033200T2 (de) 2000-02-24
GR3031459T3 (en) 2000-01-31
JPH05504566A (ja) 1993-07-15
USRE35492E (en) 1997-04-08

Similar Documents

Publication Publication Date Title
ATE181835T1 (de) Wundbehandlung mittels biologisch aktiver peptide
ES2196640T3 (es) Dispositivo terapeutico transdermico con capsaicina y analogos de capsaicina.
ES2186693T3 (es) Uso combinado del acido hialuronico y de agentes terapeuticos para mejorar el efecto terapeutico.
ATE107858T1 (de) Pharmazeutische zusammensetzung zum abnehmen.
ES2043890T3 (es) Nuevo uso medico.
ES2162615T3 (es) Metodo para tratar o prevenir diabetes de tipo 1 mediante la administracion oral de insulina.
SE8902638L (sv) Stabiliserade protein- eller peptidkonjugat
TR199801180T2 (xx) Aneljestik etkiye sahip yeni bile�ikler.
ID17768A (id) Metoda pengobatan
SE8501050D0 (sv) Biologically active fragments of human antihemophilic factor and method for preparation thereof
RU95106651A (ru) Аналоги дзе-тур динорфина и способ лечения толерантных состояний у пациента
DE69116380T2 (de) Pharmazeutische zubereitung zur behandlung verlängerter gerinnungszeit
PT687184E (pt) Adenovirus recombinantes e sua utilizacao em terapia genica para o tratamento de patologias oculares
DE69625682D1 (de) Verfahren zur behandlung von entzündungen und zusammensetzungen dafür
ATE103804T1 (de) Pharmazeutische praeparate.
TR199801184T2 (xx) Analjezik tesirli yeni bile�ikler.
ATE107170T1 (de) Zusammensetzung und behandelung mittels biologisch aktiven peptiden und bestimmten anionen.
GEP20012377B (en) Use of Trophoblastic Beta-1 Glycoprotein for Treating Auto-Immune Diseases and Method of Treatment These Diseases
NO961180L (no) Transdermal anordning inneholdende (E)-2-(p-fluorfenetyl)-3-fluorallylamin for behandling av Alzheimers sykdom
RU94044795A (ru) Способ лечения невралгии тройничного нерва
RU96122371A (ru) Способ лечения эндогенных и послеоперационных увеитов
RU95102184A (ru) Способ лечения синдрома после тотальной оварэктомии
RU95106400A (ru) Способ предупреждения и лечения дифтерийных нейропатий в эксперименте
RU94045317A (ru) Способ лечения вилюйского энцефаломиелита
RU94037731A (ru) Способ лечения рассеянного склероза

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification
EEFA Change of the company name
REN Ceased due to non-payment of the annual fee